Laboratory Stakeholders Urge FDA To Ditch IVDMIA Guidance, Pursue Rule

FDA should start over in its efforts to claim regulatory oversight of a new class of high-tech laboratory-developed tests through a guidance document and begin a formal rulemaking process, diagnostic industry stakeholders said at a Feb. 8 hearing